

AMENDMENTS TO THE CLAIMS

Claims 1 and 2 (previously cancelled)

Claim 3 (previously amended)

The method of claim 8, wherein the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-0-methyl-alpha-6-ribohexopyranosyl)oxy)-6-0-methyl-3-oxo-12,11-([oxycarbonyl [[[2-[4-(3-pyridinyl)-1H-imidazol-1-yl]ethoxy]-methyl]imino]]erythromycin.

Claim 4 (previously amended)

The method of claim 8, wherein the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-0-methyl-alpha-L-ribohexopyranosyl)oxy)-6-0-methyl-3-oxo-12,11-(oxycarbonyl((4-(3-(3-pyridinyl)-1H-1,2,4-triazol-1-yl)butyl)imino))erythromycin.

Claim 5 (previously amended)

The method of claim 8, wherein the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-0-methyl-alpha-L-ribohexopyranosyl)oxy)-2-fluoro-6-0-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))erythromycin (A isomer).

Claim 6 (previously amended)

The method of claim 8, wherein the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribohexopyranosyl)oxy)-6-O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))erythromycin.


Claim 7 (previously cancelled)

Claim 8 (currently amended)

A method of treating atherosclerosis ~~preventing the arterial complications~~ in a patient comprising selecting a patient with atherosclerosis ~~arterial complications~~ and administering to said patient an effective amount of a ketolide or its non-toxic, pharmaceutically acceptable acid addition salts sufficient to treat atherosclerosis ~~prevent arterial complications~~ in said patient.

Claim 9 (previously added)

The method of claim 8 wherein the ketolide has the formula



wherein R is $-(CH_2)_mO_n(X)YAr$, m and n are individually 0 or 1, X is selected from the group consisting of $-(NH)_a-$, $-CH_2-$ and $-SO_2-$, a is 0 or 1, Y is $-(CH_2)_b-(CH=CH)_c-$ $(CH_2)_d-$, c is 0 or 1, $b + c + d \leq 8$, Z is hydrogen or halogen and Ar is unsubstituted or substituted aryl or heteroaryl.

Claim 10 (previously added)

The method of claim 8 wherein the ketolide is orally administered at 50 to 500 mg per day.